2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103547R
    L-168049 (Standard) 191034-25-0
    L-168049 (Standard) is the analytical standard of L-168049 (HY-103547). This product is intended for research and analytical applications. L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively.
    L-168049 (Standard)
  • HY-103566R
    LY456236 (Standard) 338736-46-2
    LY456236 (Standard) is the analytical standard of LY456236 (HY-103566). This product is intended for research and analytical applications. LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 has anticonvulsant effects and blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research.
    LY456236 (Standard)
  • HY-103683R
    PF-06409577 (Standard) 1467057-23-3 98%
    PF-06409577 (Standard) is the analytical standard of PF-06409577. This product is intended for research and analytical applications. PF-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 isoform with an EC50 of 7 nM.
    PF-06409577 (Standard)
  • HY-103704R
    LY2562175 (Standard) 1103500-20-4
    LY2562175 (Standard) is the analytical standard of LY2562175 (HY-103704). This product is intended for research and analytical applications. LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM.
    LY2562175 (Standard)
  • HY-103721R
    SIRT6-IN-2 (Standard) 891002-11-2 98%
    SIRT6-IN-2 (Standard) is the analytical standard of SIRT6-IN-2 (HY-103721). This product is intended for research and analytical applications. SIRT6-IN-2 (Compound 5) is a selective and competitive SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects.
    SIRT6-IN-2 (Standard)
  • HY-104032R
    Ac-CoA Synthase-IN-1 (Standard) 508186-14-9
    Ac-CoA Synthase-IN-1 (Standard) is the analytical standard of Ac-CoA Synthase-IN-1 (HY-104032). This product is intended for research and analytical applications. Ac-CoA Synthase-IN-1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 μM. Ac-CoA Synthase-IN-1 inhibits the respiratory syncytial virus (RSV).
    Ac-CoA Synthase-IN-1 (Standard)
  • HY-104050R
    M-31850 (Standard) 281224-40-6 98%
    M-31850 (Standard) is the analytical standard of M-31850 (HY-104050). This product is intended for research and analytical applications. M-31850 is a potent, selective and competitive β-hexosaminidase (Hex) inhibitor with IC50s of 6.0 μM and 3.1 μM for human HexA and human HexB, respectively. M-31850 also competitively inhibits β-N-acetyl-D-hexosaminidase OfHex2 with a Ki of 2.5 μM.
    M-31850 (Standard)
  • HY-104073R
    CAY10602 (Standard) 374922-43-7
    CAY10602 (Standard) is the analytical standard of CAY10602 (HY-104073). This product is intended for research and analytical applications. CAY10602 is a SIRT1 activator. CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells.
    CAY10602 (Standard)
  • HY-10450S2
    Dapagliflozin-d4 1224234-25-6 98%
    Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin-d4
  • HY-10457AR
    Velusetrag hydrochloride (Standard) 866933-51-9 98%
    Velusetrag hydrochloride (Standard) is the analytical standard of Velusetrag hydrochloride (HY-10457A). This product is intended for research and analytical applications. Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin 5-HT4 receptor (5-HT4R), with a pKi of 7.7. Velusetrag hydrochloride exhibits no affinity (Ki>10 μM) for 5-HT2A and 5-HT2B receptors. Velusetrag hydrochloride can be used for the research of gastrointestinal diseases and Parkinson's disease.
    Velusetrag hydrochloride (Standard)
  • HY-105074R
    Farglitazar (Standard) 196808-45-4 98%
    Farglitazar (Standard) is the analytical standard of Farglitazar (HY-105074). This product is intended for research and analytical applications. Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
    Farglitazar (Standard)
  • HY-105185R
    Fidarestat (Standard) 136087-85-9 98%
    Fidarestat (Standard) is the analytical standard of Fidarestat (HY-105185). This product is intended for research and analytical applications. Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
    Fidarestat (Standard)
  • HY-105318R
    LGD-2226 (Standard) 328947-93-9
    LGD-2226 (Standard) is the analytical standard of LGD-2226 (HY-105318). This product is intended for research and analytical applications. LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction.
    LGD-2226 (Standard)
  • HY-105935R
    Keracyanin chloride (Standard) 18719-76-1
    Keracyanin (chloride) (Standard) is the analytical standard of Keracyanin (chloride). This product is intended for research and analytical applications. Keracyanin chloride inhibits NF-κB/FAK/MAPK signaling pathway. Keracyanin chloride exhibits antioxidant, anti-inflammatory and hypoglycemic effects, and is orally active.
    Keracyanin chloride (Standard)
  • HY-106011R
    SLX-4090 (Standard) 913541-47-6
    SLX-4090 (Standard) is the analytical standard of SLX-4090 (HY-106011). This product is intended for research and analytical applications. SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia.
    SLX-4090 (Standard)
  • HY-106019R
    Liarozole (Standard) 115575-11-6 98%
    Liarozole (Standard) is the analytical standard of Liarozole. This product is intended for research and analytical applications. Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties.
    Liarozole (Standard)
  • HY-106130R
    Implitapide (Standard) 177469-96-4 98%
    Implitapide (Standard) is the analytical standard of Implitapide (HY-106130). This product is intended for research and analytical applications. Implitapide (AEGR 427) is a microsomal triglyceride transfer protein (MTP) inhibitor.
    Implitapide (Standard)
  • HY-106181R
    Rivoglitazone (Standard) 185428-18-6 98%
    Rivoglitazone (Standard) is the analytical standard of Rivoglitazone (HY-106181). This product is intended for research and analytical applications. Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the research of type 2 diabetes mellitus.
    Rivoglitazone (Standard)
  • HY-106198R
    Lidorestat (Standard) 245116-90-9 98%
    Lidorestat (Standard) is the analytical standard of Lidorestat (HY-106198). This product is intended for research and analytical applications. Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
    Lidorestat (Standard)
  • HY-106203R
    Crinecerfont (Standard) 752253-39-7 98%
    Crinecerfont (Standard) is the analytical standard of Crinecerfont (HY-106203). This product is intended for research and analytical applications. Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont (Standard)
Cat. No. Product Name / Synonyms Application Reactivity